Treatment of benign phylloids tumor

Reading File

Finding Sources

Searching PubMed

"phyllodes tumor" AND treatment AND surgery

Reading File

I now have comprehensive, multi-source textbook content. Here is the full answer:

Treatment of Benign Phyllodes Tumor

Background

Benign phyllodes tumors are rare fibroepithelial neoplasms accounting for 0.5%-1% of all breast tumors. They are classified as benign, borderline, or malignant by the WHO based on stromal cellularity, stromal atypia, stromal overgrowth, mitotic rate (<5/10 hpf for benign), and tumor margins (pushing vs. infiltrative). Benign tumors comprise >50% of all phyllodes tumors. They most commonly affect women aged 40-50 and often clinically mimic a fibroadenoma.

Diagnosis Before Treatment

Core needle biopsy (CNB) is required to confirm the diagnosis. Note that CNB carries a false-negative rate of 25%-30% for phyllodes tumors - distinguishing benign phyllodes from fibroadenoma on minimal tissue is particularly difficult.
A CNB reported as "cellular fibroepithelial lesion" (indeterminate) should be treated as a potential phyllodes tumor and excised.
In the setting of a rapidly enlarging mass, excisional biopsy should be performed even if CNB is negative.

Definitive Treatment: Surgical Excision

Surgery is the only treatment for benign phyllodes tumor. There are no adjuvant therapy recommendations.

Key Surgical Principles

Principle	Detail
All benign phyllodes tumors must be excised	Unlike fibroadenomas, observation is not acceptable - excision is necessary for local control and to rule out malignancy
Negative margins	The goal is clear histologic margins; margin width has evolved - most surgeons prefer "no tumor at ink" to 2 mm (some sources cite 1-2 cm as the traditional target)
Breast-conserving surgery (BCS)	Preferred approach; even large tumors can be treated with BCS without compromising cancer-specific survival
Mastectomy	Reserved for massive tumors or large tumors in a small breast where adequate margins cannot be achieved with BCS
Axillary lymph node dissection	Not indicated - lymph node involvement is rare (only ~8/498 patients in SEER data had nodal involvement)
Sentinel lymph node biopsy (SLNB)	Not routinely performed

Re-excision

Reexcision is rarely necessary for benign phyllodes tumors with clear margins.
Reexcision is recommended if borderline or malignant features are identified on final pathology.

Adjuvant Therapy

No adjuvant radiation, chemotherapy, or endocrine therapy is recommended for benign phyllodes tumors.
Radiation and chemotherapy may be considered for large borderline or malignant phyllodes tumors only.

Prognosis and Follow-Up

Local recurrence rate: ~10% for benign phyllodes tumors, primarily associated with involved (positive) margins.
Distant metastasis: Older studies reported ~10% metastatic rate at 5 years; newer data with standardized WHO classification reports <1%, most commonly to the lung.
No specific surveillance imaging protocol is required for benign phyllodes (unlike malignant phyllodes, where chest X-ray every 6 months for 2 years is recommended).

Summary

The cornerstone of treatment for benign phyllodes tumor is wide local excision to negative margins. Mastectomy is reserved for cases where adequate margins cannot otherwise be achieved. No adjuvant therapy is needed. The prognosis is excellent, though local recurrence occurs in ~10% of cases when margins are involved.

Sources:

Current Surgical Therapy, 14e, p. 761
Fischer's Mastery of Surgery, 8e, p. 1377
Mulholland and Greenfield's Surgery, 7e, pp. 3977-3978
Berek & Novak's Gynecology, pp. 985-986

Recent literature note: Three systematic reviews (PMIDs 37611540, 37415652, 42196354) published 2023-2026 focus on malignant and metastatic phyllodes tumors and do not change the established approach for benign disease. Treatment of benign phyllodes remains wide local excision to clear margins with no adjuvant therapy.

Treat of fat necrosis of breast

Finding Sources

Searching PubMed

"fat necrosis" AND breast AND management

Finding Sources

Reading File

I now have a comprehensive multi-source picture. Here is the full answer:

Treatment of Fat Necrosis of the Breast

What Is It?

Fat necrosis is a benign, non-neoplastic condition resulting from inflammation and disruption of the blood supply to fat cells, leading to cell death. It is clinically important primarily because it can closely mimic breast carcinoma - producing a palpable mass, skin thickening, nipple retraction, and suspicious mammographic findings, making it a diagnostic challenge rather than a therapeutic one.

Causes

Trauma (only ~50% of patients recall a specific injury)
Prior surgery (lumpectomy, breast reconstruction, fat grafting/lipomodelling)
Radiation therapy (RT)
Anticoagulation
Infection

Clinical & Imaging Features

Feature	Detail
Presentation	Hard palpable mass, ecchymosis, skin thickening, erythema, nipple retraction
Mammography	Encapsulated fat-density mass; coarse calcifications; "oil cyst" with thin eggshell rim (pathognomonic when present)
Ultrasound	Round/oval smooth-bordered hypo- or anechoic mass; acoustic shadowing if calcified; no internal vascularity
Key concern	Cannot reliably be distinguished from cancer on imaging alone

Diagnosis: Excluding Malignancy First

Because fat necrosis is radiographically indistinguishable from carcinoma in many cases, biopsy is essential before any management decision:

Core needle biopsy (CNB) is the standard first step - using a large-bore needle (≤14 gauge) with adequate sampling
Concordance between radiologic and pathologic findings must be confirmed
If CNB is concordant for fat necrosis and adequately sampled, observation (non-surgical management) is appropriate
If imaging-pathology is discordant, or if clinical concern persists, excisional biopsy is warranted

Treatment

1. Observation (Conservative/Non-operative) - First-Line for Most Cases

Fat necrosis has no malignant potential
If untreated, the mass gradually disappears spontaneously over time
Observation is safe when:
- Biopsy confirms fat necrosis (adequate sampling, ≤14-gauge needle)
- Radiologic-pathologic concordance is established
- The lesion is clinically stable
For fat grafting-related nodules specifically: if the nodule is subcutaneous, <0.5 cm, with no skin changes, serial clinical examination is safe; ultrasound and biopsy are reserved for change in size or character
If the lesion on ultrasound is definitively fat necrosis: clinical observation and repeat ultrasound in 6 months

2. Surgical Excision - Selected Cases Only

Surgery is not routinely required but is indicated when:

The diagnosis remains uncertain after imaging and biopsy (cannot exclude carcinoma)
The patient's quality of life is significantly affected by the mass
The lesion is persistent, enlarging, or symptomatic
Excisional biopsy is required for definitive diagnosis in discordant cases

Key Points Summary

Principle	Recommendation
Malignant potential	None - benign condition
Natural history	Spontaneous resolution is common
First-line management	Observation after confirmed biopsy
Biopsy indication	When cannot distinguish from carcinoma
Surgery	Reserved for diagnostic uncertainty or symptomatic/quality-of-life impact
Adjuvant therapy	Not applicable

Sources:

Current Surgical Therapy, 14e, p. 761
Fischer's Mastery of Surgery, 8e, pp. 1378-1379
Berek & Novak's Gynecology, p. 986-987
Sabiston Textbook of Surgery, p. 1386
Robbins, Cotran & Kumar Pathologic Basis of Disease, p. (Fat Necrosis section)

Recent evidence note: No recent systematic reviews specifically address benign breast fat necrosis management in isolation - the 2023-2026 PubMed literature on fat necrosis in the breast largely addresses it as a complication of reconstruction and RT. The established approach above (observe if confirmed benign, excise if uncertain) remains the standard of care.

This is a shared conversation. Sign in to Orris to start your own chat.